Tsinghua AIR and Shuimu Molecular Open-Source OpenBioMed, Redefining AI in Pharma

The Institute for Intelligent Industrial Research (AIR) at Tsinghua University, in collaboration with Shuimu Molecular, has launched and open-sourced OpenBioMed Skills—a suite of large language model plugins for biomedical research. This pioneering project translates expert biomedical decision-making processes into executable Agent Skill code and is publicly available on GitHub. The initial release features 45 core skills spanning five critical domains: biochemistry and drug development, protein analysis and design, single-cell omics analysis, and data retrieval tool integration. It aims to overcome engineering barriers across the entire biomedical R&D pipeline.
By deploying OpenBioMed Skills on its namesake open-source platform, researchers can directly access specialized multimodal models such as PharMolixFM, BioMedGPT-R1, and MutaPLM. Compared to general-purpose large language models like ChatGPT, this system shows marked advantages in comprehending domain-specific knowledge and executing pharmaceutical research logic. It also supports remote management of biomedical Agents via mobile applications including Feishu, DingTalk, and WeChat.
Nie Zaiqing, Chief Researcher at Tsinghua University and Chief Scientist at Shuimu Molecular, noted that this initiative represents a shift in drug development—from reliance on expert intuition toward intelligent, collaborative innovation. In the era of AI for Science, OpenBioMed Skills enables natural language to drive complex pharmaceutical workflows through systematic, coded processes. This provides robust infrastructure for advancing next-generation drug discovery paradigms.
Related article
U.S. Stocks Hit Historic Milestone as AI and Aerospace Giants Prepare for Trillion-Dollar Debut
Elon Musk, Sam Altman, and Dario Amodei, three titans of the technology sector, are advancing toward initial public offerings for their respective ventures. With SpaceX, OpenAI, and Anthropic—three industry behemoths nearing trillion-dollar valuation
Swedish AI Startup Lovable Eyes $13.2 Billion Valuation After Major Funding Round
As AI-driven coding tools gain traction, Swedish startup Lovable has secured a major funding round. The company aims to raise $3 billion, potentially boosting its valuation to $13.2 billion—double the $6.6 billion recorded last December. Menlo Ventur
Google Tests Remy AI Agent for Gemini as Focus Shifts to User Control
According to Business Insider, Google is testing Remy, a new AI personal agent for Gemini. This tool aims to execute tasks on behalf of users, streamlining both professional workflows and daily routines.Currently, Remy is undergoing testing in an int
Related Special Topic Recommendations
Comments (0)
0/500

The Institute for Intelligent Industrial Research (AIR) at Tsinghua University, in collaboration with Shuimu Molecular, has launched and open-sourced OpenBioMed Skills—a suite of large language model plugins for biomedical research. This pioneering project translates expert biomedical decision-making processes into executable Agent Skill code and is publicly available on GitHub. The initial release features 45 core skills spanning five critical domains: biochemistry and drug development, protein analysis and design, single-cell omics analysis, and data retrieval tool integration. It aims to overcome engineering barriers across the entire biomedical R&D pipeline.
By deploying OpenBioMed Skills on its namesake open-source platform, researchers can directly access specialized multimodal models such as PharMolixFM, BioMedGPT-R1, and MutaPLM. Compared to general-purpose large language models like ChatGPT, this system shows marked advantages in comprehending domain-specific knowledge and executing pharmaceutical research logic. It also supports remote management of biomedical Agents via mobile applications including Feishu, DingTalk, and WeChat.
Nie Zaiqing, Chief Researcher at Tsinghua University and Chief Scientist at Shuimu Molecular, noted that this initiative represents a shift in drug development—from reliance on expert intuition toward intelligent, collaborative innovation. In the era of AI for Science, OpenBioMed Skills enables natural language to drive complex pharmaceutical workflows through systematic, coded processes. This provides robust infrastructure for advancing next-generation drug discovery paradigms.
U.S. Stocks Hit Historic Milestone as AI and Aerospace Giants Prepare for Trillion-Dollar Debut
Elon Musk, Sam Altman, and Dario Amodei, three titans of the technology sector, are advancing toward initial public offerings for their respective ventures. With SpaceX, OpenAI, and Anthropic—three industry behemoths nearing trillion-dollar valuation
Swedish AI Startup Lovable Eyes $13.2 Billion Valuation After Major Funding Round
As AI-driven coding tools gain traction, Swedish startup Lovable has secured a major funding round. The company aims to raise $3 billion, potentially boosting its valuation to $13.2 billion—double the $6.6 billion recorded last December. Menlo Ventur





Home






